Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Multiple system atrophy, parkinsonian type (MSA-p) is a form of multiple system atrophy (MSA) with predominant parkinsonian features (bradykinesia, rigidity, irregular jerky postural tremor, and postural instability).
Biomarker and diagnostic research for multiple system atrophy, parkinsonian type has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
2 clinical trials registered, 2 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
107 publications have been identified in PubMed for multiple system atrophy, parkinsonian type. Kisho has analyzed 77 by research type. Research spans Diagnostic / Biomarker (39%), Basic Science / Preclinical (27%), and Case Report / Case Series (13%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 30 |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 3:43 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research | 21 | 27% |
Patient case studies | 10 | 13% |
Disease patterns and progression | 9 | 12% |
Research summaries | 5 | 6% |
Clinical study results | 2 | 3% |
Soriano AP (2026). [PMID: 41519992](https://pubmed.ncbi.nlm.nih.gov/41519992/). *NPJ Parkinsons Dis*. [Diagnostic / Biomarker]
Zhao Y (2026). [PMID: 42206952](https://pubmed.ncbi.nlm.nih.gov/42206952/). *J Parkinsons Dis*. [Epidemiology / Natural History]
Fecek C (2026). [PMID: 32809337](https://pubmed.ncbi.nlm.nih.gov/32809337/). *Unknown Journal*. [Basic Science / Preclinical]
Schneller M (2026). [PMID: 41770321](https://pubmed.ncbi.nlm.nih.gov/41770321/). *J Neural Transm (Vienna)*. [Review / Meta-Analysis]
Sorrentino C (2026). [PMID: 41504651](https://pubmed.ncbi.nlm.nih.gov/41504651/). *Expert Rev Neurother*. [Review / Meta-Analysis]
Tagnin L (2026). [PMID: 42203967](https://pubmed.ncbi.nlm.nih.gov/42203967/). *Eur J Nucl Med Mol Imaging*. [Diagnostic / Biomarker]
Hou C (2026). [PMID: 42099972](https://pubmed.ncbi.nlm.nih.gov/42099972/). *Front Neurol*. [Diagnostic / Biomarker]
Yang H (2026). [PMID: 41443377](https://pubmed.ncbi.nlm.nih.gov/41443377/). *Neurobiol Dis*. [Diagnostic / Biomarker]
Chang HJ (2026). [PMID: 41790245](https://pubmed.ncbi.nlm.nih.gov/41790245/). *J Neurol*. [Basic Science / Preclinical]
Beach PA (2026). [PMID: 41171539](https://pubmed.ncbi.nlm.nih.gov/41171539/). *Clin Auton Res*. [Basic Science / Preclinical]
AI-curated news mentioning multiple system atrophy, parkinsonian type
Updated Aug 31, 2026
Recent research highlights the potential of plasma neurofilament light as a biomarker for early differentiation between multiple system atrophy and Parkinson's disease. This discovery could enhance diagnostic accuracy and improve patient management strategies.
Recent research highlights the complexities of multiple system atrophy, a rare neurodegenerative disorder. The study provides insights into potential biomarkers and therapeutic targets for this challenging condition.
A 2-year prospective cohort study identifies magnetic resonance imaging markers that can predict disease progression in early-stage multiple system atrophy. This research enhances understanding of disease dynamics and may inform future therapeutic strategies.
Lundbeck has completed patient randomization ahead of schedule in its Phase 3 Mascot study for a potential first-in-class therapy targeting multiple system atrophy. This milestone positions the company favorably in the competitive landscape for rare neurodegenerative diseases.